SPARC completes enrolment in PROSEEK, Phase 2 study of Vodobatinib in early Parkinson’s disease
506 patients completed enrolment across 84 sites in the US, Europe and India
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.